阅读说明：本技术 低容量血浆置换用于治疗早期和中期的阿尔茨海默病的用途 (Use of low volume plasmapheresis for the treatment of early and intermediate stage alzheimer's disease ) 是由 维克托·基立福罗拉 安东尼奥·曼纽尔·帕兹雷加德拉 劳拉·努涅斯多梅内克 于 2019-10-23 设计创作，主要内容包括：本发明涉及一种包含5％(w/v)和25％(w/v)之间的浓度的人类白蛋白的组合物,所述组合物用于借助于低容量血浆置换(low volume plasma exchange,LVPE)治疗轻度阿尔兹海默病和中度阿尔茨海默病。(The present invention relates to a composition comprising human albumin at a concentration between 5% (w/v) and 25% (w/v) for use in the treatment of mild and moderate alzheimer's disease by means of Low Volume Plasma Exchange (LVPE).)

1. A composition comprising human albumin at a concentration between 5% (w/v) and 25% (w/v) for use in the treatment of mild Alzheimer's Disease (AD) and moderate Alzheimer's Disease (AD) by Low Volume Plasma Exchange (LVPE).

2. The composition for use according to claim 1, characterized in that said LVPE regimen involves a blood volume between 600mL-900 mL.

3. Composition for use according to claim 1 or 2, characterized in that the treatment regimen comprises the administration to the patient of three or more rounds of LVPE.

4. Composition for use according to any one of the preceding claims, characterized in that prior rounds of conventional Therapeutic Plasmapheresis (TPE) are carried out prior to the treatment regimen of LVPE.

5. Composition for use in accordance with claim 4, characterized in that the TPE regimen can be carried out with a frequency of 1 TPE/week.

6. Composition for use in accordance with claim 4 or 5, characterized in that the TPE regimen is carried out for at least 6 weeks.

7. Composition for use according to any one of the preceding claims, characterized in that the LVPE of each subsequent round is carried out 10-45 days after the previous round.

8. Composition for use in accordance with claim 7, characterized in that the LVPE of each subsequent round is performed 15-35 days after the previous round.

9. Composition for use in accordance with claim 8, characterized in that the LVPE of each subsequent round is performed 30 days after the previous round.

10. Composition for use in accordance with one of the preceding claims, characterized in that between 10g and 40g of albumin is used for the displacement in each round of LVPE.

11. Composition for use according to claim 10, characterized in that between 20g and 40g of albumin is used for displacement in each round of LVPE.

12. Composition for use according to any one of the preceding claims, characterized in that said treatment additionally comprises the administration of intravenous immunoglobulin (IGIV).

13. Composition for use according to claim 12, characterized in that between 10g and 20g of immunoglobulins are used for replacement in certain rounds of LVPE, but never administered simultaneously with albumin.

14. Composition for use according to any one of the preceding claims, characterized by being used for treating patients suffering from moderate Alzheimer's Disease (AD).